| Detected | Trial | Change |
|---|---|---|
| 2026-07-31 | NCT06113016 Prevention of Frailty With Fisetin and Exercise in Breast Cancer Survivors |
date change Primary completion pushed: 2028-06-30 -> 2028-10-31 |
| 2026-07-31 | NCT06113016 Prevention of Frailty With Fisetin and Exercise in Breast Cancer Survivors |
date change Completion pushed: 2028-12-30 -> 2031-10-31 |
| 2026-07-21 | NCT07089641 ERAS-801 for the Treatment of Resectable and Progressive or Recurrent or Elderly Newly… |
Primary endpoint(s) modified |
| 2026-07-21 | NCT07089641 ERAS-801 for the Treatment of Resectable and Progressive or Recurrent or Elderly Newly… |
Enrollment increased: 10 -> 50 participants |
| 2026-07-21 | NCT07089641 ERAS-801 for the Treatment of Resectable and Progressive or Recurrent or Elderly Newly… |
Trial arms changed: 1 -> 3 |
| 2026-07-19 | NCT05115760 Pea Protein Oral Nutrition Supplement for the Reduction of Gastrostomy Tube Placement… |
date change Primary completion pushed: 2026-06-01 -> 2027-06-01 |
| 2026-07-19 | NCT05115760 Pea Protein Oral Nutrition Supplement for the Reduction of Gastrostomy Tube Placement… |
date change Completion pushed: 2027-06-01 -> 2028-06-01 |
| 2026-07-19 | NCT04857502 99mTc-PSMA-I&S Biodistribution in Patients With Prostate Cancer |
date change Primary completion pushed: 2026-06-01 -> 2027-06-01 |
| 2026-07-19 | NCT04857502 99mTc-PSMA-I&S Biodistribution in Patients With Prostate Cancer |
date change Completion pushed: 2027-06-01 -> 2028-06-01 |
| 2026-07-19 | NCT04395079 Brachytherapy With Durvalumab or Tremelimumab for the Treatment of Patients With… |
date change Completion moved earlier: 2026-12-01 -> 2026-10-11 |
| First Posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-07-21 | NCT07716735 Mercaptopurine for the Treatment of Hereditary Leiomyomatosis and Renal Cell Carcinoma… | Phase 1 | Not Yet Recruiting |
| 2026-07-20 | NCT07714421 Epcoritamab and Pola-R-mini-CHP for the Treatment of Diffuse Large B Cell Lymphoma in… | Phase 1 | Not Yet Recruiting |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 4 | |||
| NCT06934239 | A Trial Comparing Screening Mammography With and Without Assistance From Artificial… | Breast Cancer Screening | Recruiting |
| Phase 3 | |||
| NCT07293585 | Vascular Optimized Radiotherapy Tuned to Critical Structures for Erectile Function Using… | Prostate Cancer | Recruiting |
| NCT07461948 | Advanced Imaging Techniques for Evaluating the Tumor Immune Microenvironment in… | Glioblastoma | Recruiting |
| NCT03582774 | Multicenter Randomized Trial of 68Ga-PSMA-11 PET/CT Based SRT After Radical Prostatectomy | Recurrent Prostate Carcinoma | Active, Not Recruiting |
| NCT06448286 | PH Weighted Chemical Exchange Saturation Transfer MRI-Based Surgical Resection to Improve… | Glioblastoma | Not Yet Recruiting |
| Phase 2 | |||
| NCT04553770 | Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of… | Early-stage Breast Cancer | Recruiting |
| NCT07185165 | An Investigational Scan (Flotufolastat F 18 PET/CT) for Detecting Residual or Recurrent… | Prostate Carcinoma | Recruiting |
| NCT07150715 | Alpha-Emitting Radionuclide or Beta-Emitting Radionuclide With Metastasis-Directed… | Oligometastatic Prostate Adenocarcinoma | Recruiting |
| NCT04712851 | Pembrolizumab for the Treatment of Cervical Intraepithelial Neoplasia | Cervical Intraepithelial Neoplasia | Recruiting |
| NCT06216249 | Phase 2 Randomized Trial of Flexible Dosing Schedule of 177Lu-PSMA-617 for the Treatment… | Prostate Carcinoma | Recruiting |
| NCT06288113 | Re-treatment With 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant… | Castration-Resistant Prostate Carcinoma | Recruiting |
| NCT07323641 | Telisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurable, Non… | Lung Non-Small Cell Carcinoma | Recruiting |
| NCT06788938 | Tarlatamab in Advanced Delta-like 3 (DLL3)-Expressing Tumors Including Neuroendocrine… | DLL3-expressing Tumors | Recruiting |
| NCT06436612 | Study of Magnetic Resonance Image and Computed Tomography-Guided Stereotactic Body… | Abdominopelvic Sarcomas | Recruiting |
| NCT06447103 | An Investigational Scan (89Zr-DFO-GmAb PET/CT) Compared to Contrast-Enhanced CT for the… | Clear Cell Renal Cell Carcinoma | Recruiting |
| NCT06980077 | Ivonescimab for the Treatment of Thymic Cancer | Thymus Carcinoma | Recruiting |
| NCT03603223 | Pembrolizumab in Treating Participants With Leukoplakia | Erythroleukoplakia | Recruiting |
| NCT05775471 | Pembrolizumab and Enfortumab Vedotin With Pembrolizumab Prior to and After Radical… | Renal Pelvis and Ureter Urothelial Carcinoma | Recruiting |
| NCT04469764 | Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer | Recurrent Endometrial Carcinoma | Recruiting |
| NCT05595499 | Fisetin to Improve Physical Function in Stage I-III Breast Cancer Survivors | Anatomic Stage I Breast Cancer AJCC v8 | Recruiting |
| NCT06067269 | Hormone Therapy (Apalutamide) and Image-guided Stereotactic Body Radiation Therapy for… | Prostate Adenocarcinoma | Recruiting |
| NCT06113016 | Prevention of Frailty With Fisetin and Exercise in Breast Cancer Survivors | Anatomic Stage I Breast Cancer American Joint Committee on Cancer (AJCC) v8 | Recruiting |
| NCT02881242 | Trametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate… | Hormone-Resistant Prostate Cancer | Active, Not Recruiting |
| NCT03825796 | CPX-351 Plus Enasidenib for Relapsed AML | Recurrent Acute Myeloid Leukemia | Active, Not Recruiting |
| NCT03732950 | Pembrolizumab in Treating Participants With Recurrent Ovarian Cancer | Recurrent Fallopian Tube Carcinoma | Active, Not Recruiting |